Insulet Corp. · PODD · FY2026 Q3 · Calendar Q4 2026

Insulet raises 2026 growth outlook as customer base and international sales expand

Q3 evidence supports a growth case built on customer-base expansion, international demand and early signs of improved retention, while competition, type 2 attrition, pricing and product execution remain material tests.

Reported Before market openNASDAQHealthcare $10.74B market cap
80quality score

Earnings scorecard

Reported versus consensus
Reported EPS — Consensus $1.59
EPS surprise — Reported versus consensus
Reported revenue — Consensus $832.6M
Revenue surprise — Reported versus consensus

Market reaction

prior-close to event-session close
Stock move +6.6% Event window
SPY move +1.7% Same window
Abnormal move +4.9% Stock minus SPY
Volume 1.9× Versus trailing sessions
Subsequent drift 0.0% Up to 20 sessions
PODDSPY benchmark

Ask FN2 about PODD FY2026 Q3

Transcript, numbers and history already loaded
What drove PODD's +6.6% move after FY2026 Q3 earnings?What changed in PODD's guidance and outlook in FY2026 Q3?Give me the bull and bear case for PODD after FY2026 Q3 earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Management reported Q3 revenue growth of about 20% year over year, with U.S. growth of 15% and international growth of 33%, and raised full-year 2026 revenue growth guidance to 21–22% constant currency. The analysis also cites early Omnipod Discover adoption benefits for retention and a customer base increase of more than 20%.

Guidance delta

Raised full-year 2026 revenue growth guidance to 21–22% constant currency. The supplied analysis does not state the prior numeric range.

Key takeaways

  • Q3 revenue was reported at $842 million, up about 20% year over year.
  • The customer base grew more than 20%; the analysis says early Omnipod Discover adoption supported retention.
  • Management raised full-year 2026 revenue growth guidance to 21–22% constant currency.
  • Management cited Omnipod 6 for 2027 and a fully closed-loop system commercial launch for 2028.

Management priorities

  • Expand global customer reach and automated insulin-delivery penetration.
  • Develop Omnipod Discover and expand sensor integration and market access.
  • Advance Omnipod 6 and the fully closed-loop system while scaling manufacturing.

Follow PODD with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
PODD EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 2 future estimate-only quarters. Q4 '23 estimate $0.66 Q4 '23 actual $1.40, beat Q1 '24 estimate $0.39 Q1 '24 actual $0.73, beat Q2 '24 estimate $0.56 Q2 '24 actual $0.55, miss Q3 '24 estimate $0.76 Q3 '24 actual $0.90, beat Q2 '25 estimate $0.92 Q2 '25 actual $1.17, beat Q3 '25 estimate $1.14 Q3 '25 actual $1.24, beat Q4 '25 estimate $1.47 Q4 '25 actual $1.55, beat Q1 '26 estimate $1.19 Q1 '26 actual $1.42, beat Q2 '26 estimate $1.47 Q2 '26 actual $1.66, beat Q3 '26 estimate $1.59 Q3 '26 actual $1.99, beat Q4 '26 estimate $1.97 Q1 '27 estimate $1.64
Show less

Analyst Consensus ?

ConsensusHold50 ratings
Bullish2856.0%
Neutral1938.0%
Bearish36.0%

Analyst 52W Price Targets

$165.02Current
$144Low
$241.72Average
$450High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 5, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Jefferies Buy BuyMaintainOct 12, 2026
Wells Fargo Equal Weight OverweightDowngradeAug 6, 2026
UBS Neutral NeutralMaintainAug 6, 2026
Truist Securities Hold BuyDowngradeAug 6, 2026
TD Cowen Hold HoldMaintainAug 6, 2026
Show 45 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $165.02. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
JefferiesMatthew Taylor$190$135.28 +15.1%Oct 12, 2026
BarclaysAnalyst unavailable$150$134.73 -9.1%Oct 6, 2026
Robert W. BairdJeff Johnson$175$134.95 +6.0%Aug 6, 2026
BernsteinAnalyst unavailable$175$131.75 +6.0%Aug 6, 2026
Leerink PartnersMike Kratky$145$133.26 -12.1%Aug 6, 2026
See 78 more

Track every rating change on PODD the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Historical context

All PODD earnings
-20.1%FY2026 Q2 · Calendar Q3 2026-9.7%FY2026 Q1 · Calendar Q2 2026+4.8%FY2025 Q4 · Calendar Q1 2026

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
CVS CVS Health Corp. FY2026 Q3 · Calendar Q4 2026 — -12.5% CVS raises 2026 outlook and plans a two-company separation
COR Cencora, Inc. FY2026 Q4 · Calendar Q4 2026 — +4.0% Cencora leans on specialty growth as FY2027 expansion requires investment
RPRX Royalty Pharma plc FY2026 Q3 · Calendar Q4 2026 — +1.4% Royalty Pharma Raises Guidance as Receipts and Co-Funding Expand
ZBH Zimmer Biomet Holdings, Inc. FY2026 Q3 · Calendar Q4 2026 — +14.6% Zimmer Biomet raises 2026 outlook as hip and technology growth offset knee weakness
MDLN Medline Inc. FY2026 Q3 · Calendar Q4 2026 — +16.2% Medline Raises 2026 Organic Sales Outlook on 10% Q3 Growth
NVO Novo Nordisk A/S FY2026 Q3 · Calendar Q4 2026 — +6.4% Novo Nordisk Q3: obesity demand supports growth, pricing and LOE remain risks

Latest beats and misses

Who reports next

Beat on EPS

Missed on EPS

Get the PODD recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-11-04T17:06:58.549156+00:00
  2. FN2 earnings calendar · 2026-11-04T01:23:13.345574+00:00
  3. Polygon adjusted daily market bars · 2026-11-04T23:10:43.394204+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-04T23:10:43.391577+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-11-04. For educational purposes only; not investment advice.